Refine
Has Fulltext
- yes (15)
Is part of the Bibliography
- yes (15)
Document Type
- Journal article (15)
Language
- English (15)
Keywords
- SARS-CoV-2 (4)
- ceramides (3)
- sphingolipids (3)
- acid sphingomyelinase (2)
- ceramide (2)
- click chemistry (2)
- Aspergillus niger (1)
- Bacillus megaterium (1)
- CCL2 (MCP-1) (1)
- CXCL8 (IL-8) (1)
Institute
- Institut für Organische Chemie (15)
- Theodor-Boveri-Institut für Biowissenschaften (8)
- Institut für Virologie und Immunbiologie (6)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (2)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Institut für Hygiene und Mikrobiologie (1)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
- Lehrstuhl für Orthopädie (1)
To circumvent time-consuming clinical trials, testing whether existing drugs are effective inhibitors of SARS-CoV-2, has led to the discovery of Remdesivir. We decided to follow this path and screened approved medications "off-label" against SARS-CoV-2. Fluoxetine inhibited SARS-CoV-2 at a concentration of 0.8 mu g/ml significantly in these screenings, and the EC50 was determined with 387 ng/ml. Furthermore, Fluoxetine reduced viral infectivity in precision-cut human lung slices showing its activity in relevant human tissue targeted in severe infections. Fluoxetine treatment resulted in a decrease in viral protein expression. Fluoxetine is a racemate consisting of both stereoisomers, while the S-form is the dominant serotonin reuptake inhibitor. We found that both isomers show similar activity on the virus, indicating that the R-form might specifically be used for SARS-CoV-2 treatment. Fluoxetine inhibited neither Rabies virus, human respiratory syncytial virus replication nor the Human Herpesvirus 8 or Herpes simplex virus type 1 gene expression, indicating that it acts virus-specific. Moreover, since it is known that Fluoxetine inhibits cytokine release, we see the role of Fluoxetine in the treatment of SARS-CoV-2 infected patients of risk groups.